VolitionRX Limited (NYSEAMERICAN:VNRX) Short Interest Up 40.0% in January

VolitionRX Limited (NYSEAMERICAN:VNRX) was the target of a large increase in short interest in January. As of January 30th, there was short interest totaling 1,565,335 shares, an increase of 40.0% from the January 15th total of 1,118,479 shares. Approximately 1.3% of the shares of the stock are short sold. Based on an average trading volume of 2,494,809 shares, the days-to-cover ratio is presently 0.6 days. Based on an average trading volume of 2,494,809 shares, the days-to-cover ratio is presently 0.6 days. Approximately 1.3% of the shares of the stock are short sold.

VolitionRX Trading Down 2.9%

NYSEAMERICAN:VNRX traded down $0.01 during trading hours on Tuesday, hitting $0.22. 371,433 shares of the company traded hands, compared to its average volume of 2,316,163. VolitionRX has a twelve month low of $0.21 and a twelve month high of $0.94. The stock has a market capitalization of $29.84 million, a price-to-earnings ratio of -0.96 and a beta of 1.28. The firm has a 50-day moving average of $0.27 and a 200 day moving average of $0.43.

About VolitionRX

VolitionRX, traded as VNRX on the NYSE American exchange, is a pioneering life sciences company focused on the development and commercialization of minimally invasive diagnostic tests for the early detection of cancer and other diseases. Utilizing proprietary technology to analyze circulating nucleosomes in blood samples, the company’s platform identifies disease-specific epigenetic and biochemical signatures. By offering blood-based screening solutions, VolitionRX aims to deliver alternatives to invasive, costly and time-consuming procedures, potentially improving patient outcomes through earlier diagnosis.

The company’s flagship product suite, branded as Nu.Q, comprises assays designed to detect biomarkers associated with a range of malignancies, including colorectal, lung and pancreatic cancers, as well as other systemic conditions.